Alcon (2U3) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2U3 Analyst Ratings

Moderate Buy

7 Buy

4 Hold

1 Sell

Based on 12 analysts giving stock ratings to

Alcon

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2U3 Stock 12 Month Forecast

Average Price Target

€74.67

▲(19.66% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Alcon in the last 3 months. The average price target is €74.67 with a high forecast of €91.32 and a low forecast of €51.57. The average price target represents a 19.66% change from the last price of €62.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"50":"€50","71":"€71","92":"€92","60.5":"€60.5","81.5":"€81.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":91.324085,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€91.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.67011391018183,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€74.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.571248,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€51.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[50,60.5,71,81.5,92],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.64,59.30800653846154,61.976013076923074,64.64401961538462,67.31202615384615,69.98003269230769,72.64803923076923,75.31604576923077,77.98405230769231,80.65205884615384,83.32006538461539,85.98807192307692,88.65607846153846,{"y":91.324085,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.64,58.02693183924475,59.41386367848951,60.800795517734265,62.187727356979025,63.57465919622378,64.96159103546853,66.3485228747133,67.73545471395805,69.1223865532028,70.50931839244755,71.89625023169232,73.28318207093707,{"y":74.67011391018183,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.64,56.250096,55.860192,55.470288,55.080384,54.69048,54.300576,53.910672,53.520768,53.130863999999995,52.74096,52.351056,51.961152,{"y":51.571248,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":62.956,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.006,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.972,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.992,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.076,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.455,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.827,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.299,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.34,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.9,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€91.32

Average Price Target€74.67

Lowest Price Target€51.57

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Christopher Pasquale

Barclays

€62.48

Hold

0.12%

Upside

Initiated

10/06/26

Alcon initiated with an Equal Weight at BarclaysAlcon initiated with an Equal Weight at Barclays

Thomas Stephan

Stifel Nicolaus

€57.41→€62.48

Hold

0.12%

Upside

Reiterated

10/06/26

Analysts Conflicted on These Healthcare Names: Alcon (NYSE: ALC), BioNTech SE (NASDAQ: BNTX) and Anixa Biosciences (NASDAQ: ANIX)

Julien Ouaddour

Bank of America Securities

€51.57

Sell

-17.35%

Downside

Reiterated

10/05/26

Alcon: Underperform Rating Reiterated as Analyst Flags Mounting Headwinds; $48 Price Target Maintained

Young Li

Jefferies

€75.86

Buy

21.58%

Upside

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and Alcon (NYSE: ALC)

Larry Biegelsen

Wells Fargo

€76.76

Buy

23.01%

Upside

Reiterated

09/18/26

Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Intuitive Surgical (ISRG)

Sam England

Berenberg Bank

€91.32

Buy

46.35%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and AbbVie (NYSE: ABBV)

Falko Friedrichs

Deutsche Bank

€75.21→€78.43

Buy

25.69%

Upside

Reiterated

08/17/26

Alcon price target raised to CHF 73 from CHF 70 at Deutsche BankAlcon price target raised to CHF 73 from CHF 70 at Deutsche Bank

Graham Doyle

UBS

€92.4→€89.18

Buy

42.91%

Upside

Reiterated

08/14/26

Analysts' Top Healthcare Picks: Alcon (ALC), Kuros Biosciences (CSBTF)

Anthony Petrone

Mizuho Securities

€75.86

Buy

21.58%

Upside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: Spruce Biosciences (NASDAQ: SPRB) and Alcon (NYSE: ALC)

Steven Lichtman

William Blair

―

Hold

―

Assigned

08/12/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Alcon (NYSE: ALC)

David Adlington

J.P. Morgan

€69.97

Hold

12.14%

Upside

Reiterated

08/12/26

J.P. Morgan Sticks to Their Hold Rating for Alcon (ALC)

David Saxon

Needham

€84.79→€87.47

Buy

40.17%

Upside

Reiterated

08/11/26

Analyst Reiterates Buy on Alcon After Q2 Beat, Raised Earnings Outlook, and Strengthening Multi-Pillar Growth Drivers

Jasper Hellweg

Argus Research

€75.86

Buy

21.58%

Upside

Reiterated

07/01/26

Alcon price target lowered to $85 from $90 at ArgusAlcon price target lowered to $85 from $90 at Argus

Brett Fishbin

KeyBanc

€78.54

Buy

25.87%

Upside

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN), Immunome (NASDAQ: IMNM) and Alcon (NYSE: ALC)

Veronika Dubajova

Citi

€99.96→€91.93

Buy

47.32%

Upside

Reiterated

06/11/26

Alcon (ALC) Gets a Buy from Citi

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Christopher Pasquale

Barclays

€62.48

Hold

0.12%

Upside

Initiated

10/06/26

Alcon initiated with an Equal Weight at BarclaysAlcon initiated with an Equal Weight at Barclays

Thomas Stephan

Stifel Nicolaus

€57.41→€62.48

Hold

0.12%

Upside

Reiterated

10/06/26

Analysts Conflicted on These Healthcare Names: Alcon (NYSE: ALC), BioNTech SE (NASDAQ: BNTX) and Anixa Biosciences (NASDAQ: ANIX)

Julien Ouaddour

Bank of America Securities

€51.57

Sell

-17.35%

Downside

Reiterated

10/05/26

Alcon: Underperform Rating Reiterated as Analyst Flags Mounting Headwinds; $48 Price Target Maintained

Young Li

Jefferies

€75.86

Buy

21.58%

Upside

Reiterated

09/22/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and Alcon (NYSE: ALC)

Larry Biegelsen

Wells Fargo

€76.76

Buy

23.01%

Upside

Reiterated

09/18/26

Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Intuitive Surgical (ISRG)

Sam England

Berenberg Bank

€91.32

Buy

46.35%

Upside

Reiterated

09/10/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and AbbVie (NYSE: ABBV)

Falko Friedrichs

Deutsche Bank

€75.21→€78.43

Buy

25.69%

Upside

Reiterated

08/17/26

Alcon price target raised to CHF 73 from CHF 70 at Deutsche BankAlcon price target raised to CHF 73 from CHF 70 at Deutsche Bank

Graham Doyle

UBS

€92.4→€89.18

Buy

42.91%

Upside

Reiterated

08/14/26

Analysts' Top Healthcare Picks: Alcon (ALC), Kuros Biosciences (CSBTF)

Anthony Petrone

Mizuho Securities

€75.86

Buy

21.58%

Upside

Reiterated

08/13/26

Analysts Offer Insights on Healthcare Companies: Spruce Biosciences (NASDAQ: SPRB) and Alcon (NYSE: ALC)

Steven Lichtman

William Blair

―

Hold

―

Assigned

08/12/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Alcon (NYSE: ALC)

David Adlington

J.P. Morgan

€69.97

Hold

12.14%

Upside

Reiterated

08/12/26

J.P. Morgan Sticks to Their Hold Rating for Alcon (ALC)

David Saxon

Needham

€84.79→€87.47

Buy

40.17%

Upside

Reiterated

08/11/26

Analyst Reiterates Buy on Alcon After Q2 Beat, Raised Earnings Outlook, and Strengthening Multi-Pillar Growth Drivers

Jasper Hellweg

Argus Research

€75.86

Buy

21.58%

Upside

Reiterated

07/01/26

Alcon price target lowered to $85 from $90 at ArgusAlcon price target lowered to $85 from $90 at Argus

Brett Fishbin

KeyBanc

€78.54

Buy

25.87%

Upside

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN), Immunome (NASDAQ: IMNM) and Alcon (NYSE: ALC)

Veronika Dubajova

Citi

€99.96→€91.93

Buy

47.32%

Upside

Reiterated

06/11/26

Alcon (ALC) Gets a Buy from Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

MDWDMediwound

OVIDOvid Therapeutics

IMUXImmunic

ASNDAscendis Pharma

AORTArtivion

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alcon

3 Months

Larry BiegelsenWells Fargo

Success Rate

13/20 ratings generated profit

Average Return

+1.80%

Copying Larry Biegelsen's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +1.80% per trade.

1 Year

Larry BiegelsenWells Fargo

Success Rate

12/20 ratings generated profit

Average Return

+3.60%

Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +3.60% per trade.

2 Years

Larry BiegelsenWells Fargo

Success Rate

10/20 ratings generated profit

Average Return

+1.90%

Copying Larry Biegelsen's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +1.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2U3 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2U3 has received 8 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. 2U3 average Analyst price target in the past 3 months is 74.67.

Each month's total comprises the sum of three months' worth of ratings.

2U3 Financial Forecast

2U3 Earnings Forecast

Next quarter’s earnings estimate for 2U3 is €0.77 with a range of €0.71 to €0.82. The previous quarter’s EPS was €0.73. 2U3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2U3 has Performed in-line its overall industry.

2U3 Sales Forecast

Next quarter’s sales forecast for 2U3 is €2.41B with a range of €2.37B to €2.45B. The previous quarter’s sales results were €2.40B. 2U3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2U3 has Performed in-line its overall industry.

2U3 Stock Forecast FAQ

What is DE:2U3’s average 12-month price target, according to analysts?

Based on analyst ratings, Alcon Inc’s 12-month average price target is 74.67.

What is DE:2U3’s upside potential, based on the analysts’ average price target?

Alcon Inc has 19.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alcon Inc a Buy, Sell or Hold?

Alcon Inc has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 4 hold ratings and 1 sell ratings.

What is Alcon Inc’s share price target?

The average share price target for Alcon Inc is 74.67. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €91.32 ,and the lowest forecast is €51.57. The average share price target represents 19.66% Increase from the current price of €62.4.

What do analysts say about Alcon Inc?

Alcon Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Alcon Inc?

To buy shares of DE:2U3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Alcon (2U3) Stock Forecast & Price Target

2U3 Analyst Ratings

2U3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alcon

2U3 Analyst Recommendation Trends

2U3 Financial Forecast

2U3 Earnings Forecast

2U3 Sales Forecast

2U3 Stock Forecast FAQ

Detailed List of Analyst Forecasts